Gupta Samir, Jacobs Elizabeth T, Baron John A, Lieberman David A, Murphy Gwen, Ladabaum Uri, Cross Amanda J, Jover Rodrigo, Liu Lin, Martinez Maria Elena
Department of Medicine, Section of Gastroenterology, Veteran Affairs San Diego Healthcare System, San Diego, California, USA.
Division of Gastroenterology, Department of Internal Medicine, University of California San Diego, La Jolla, California, USA.
Gut. 2017 Mar;66(3):446-453. doi: 10.1136/gutjnl-2015-310196. Epub 2015 Dec 11.
For individuals with 1-2 small (<1 cm) low-risk colorectal adenomas, international guidelines range from no surveillance to offering surveillance colonoscopy in 5-10 years. We hypothesised that the risks for metachronous advanced neoplasia (AN) among patients with low-risk adenomas differ based on clinical factors distinct from those currently used.
We pooled data from seven prospective studies to assess the risk of metachronous AN. Two groups with 1-2 small adenomas were defined based on guidelines from the UK (n=4516) or the European Union (EU)/US (n=2477).
Absolute risk of metachronous AN ranged from a low of 2.9% to a high of 12.2%, depending on specific risk factor and guideline used. For the UK group, the highest absolute risks for metachronous AN were found among individuals with a history of prior polyp (12.2%), villous histology (12.2%), age ≥70 years (10.9%), high-grade dysplasia (10.9%), any proximal adenoma (10.2%), distal and proximal adenoma (10.8%) or two adenomas (10.1%). For the EU/US group, the highest absolute risks for metachronous AN were among individuals with a history of prior polyp (11.5%) or the presence of both proximal and distal adenomas (11.0%). In multivariate analyses, strong associations for increasing age and history of prior polyps and odds of metachronous AN were observed, whereas more modest associations were shown for baseline proximal adenomas and those with villous features.
Risks of metachronous AN among individuals with 1-2 small adenomas vary according to readily available clinical characteristics. These characteristics may be considered for recommending colonoscopy surveillance and require further investigation.
对于患有1 - 2个小(<1厘米)低风险结直肠腺瘤的个体,国际指南的建议范围从无需监测到5 - 10年后进行监测结肠镜检查。我们假设,低风险腺瘤患者发生异时性进展性腺瘤(AN)的风险因不同于当前所用的临床因素而异。
我们汇总了七项前瞻性研究的数据,以评估异时性AN的风险。根据英国(n = 4516)或欧盟/美国(n = 2477)的指南,定义了两组患有1 - 2个小腺瘤的患者。
异时性AN的绝对风险范围从低至2.9%到高至12.2%,这取决于所使用的特定风险因素和指南。对于英国组,异时性AN的最高绝对风险出现在有息肉病史的个体(12.2%)、绒毛状组织学(12.2%)、年龄≥70岁(10.9%)、高级别异型增生(10.9%)、任何近端腺瘤(10.2%)、远端和近端腺瘤(10.8%)或两个腺瘤(10.1%)中。对于欧盟/美国组,异时性AN的最高绝对风险出现在有息肉病史的个体(11.5%)或同时存在近端和远端腺瘤的个体(11.0%)中。在多变量分析中,观察到年龄增长和息肉病史增加与异时性AN的几率之间存在强关联,而基线近端腺瘤和具有绒毛状特征的腺瘤与异时性AN的关联则较为适度。
患有1 - 2个小腺瘤的个体发生异时性AN的风险因易于获得的临床特征而异。这些特征可用于推荐结肠镜监测,并需要进一步研究。